NO339364B1 - Humant immunglobulin som spesifikt bindes til det humane EpCAM-antigen, sammensetning omfattende dette, samt anvendelse for fremstilling av et medikament for behandling av tumorsykdom. - Google Patents

Humant immunglobulin som spesifikt bindes til det humane EpCAM-antigen, sammensetning omfattende dette, samt anvendelse for fremstilling av et medikament for behandling av tumorsykdom. Download PDF

Info

Publication number
NO339364B1
NO339364B1 NO20064136A NO20064136A NO339364B1 NO 339364 B1 NO339364 B1 NO 339364B1 NO 20064136 A NO20064136 A NO 20064136A NO 20064136 A NO20064136 A NO 20064136A NO 339364 B1 NO339364 B1 NO 339364B1
Authority
NO
Norway
Prior art keywords
cancer
epcam
immunoglobulin
administration
days
Prior art date
Application number
NO20064136A
Other languages
English (en)
Norwegian (no)
Other versions
NO20064136L (no
Inventor
Mathias Locher
Nadja Prang
Cornelia Quadt
Malte Peters
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of NO20064136L publication Critical patent/NO20064136L/no
Publication of NO339364B1 publication Critical patent/NO339364B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20064136A 2004-02-13 2006-09-13 Humant immunglobulin som spesifikt bindes til det humane EpCAM-antigen, sammensetning omfattende dette, samt anvendelse for fremstilling av et medikament for behandling av tumorsykdom. NO339364B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (2)

Publication Number Publication Date
NO20064136L NO20064136L (no) 2006-11-07
NO339364B1 true NO339364B1 (no) 2016-12-05

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064136A NO339364B1 (no) 2004-02-13 2006-09-13 Humant immunglobulin som spesifikt bindes til det humane EpCAM-antigen, sammensetning omfattende dette, samt anvendelse for fremstilling av et medikament for behandling av tumorsykdom.

Country Status (23)

Country Link
US (3) US20050180979A1 (https=)
EP (2) EP2107071A3 (https=)
JP (1) JP5220315B2 (https=)
KR (1) KR101236224B1 (https=)
CN (1) CN1976951B (https=)
AT (1) ATE437186T1 (https=)
AU (1) AU2005215874B2 (https=)
BR (1) BRPI0507660A (https=)
CA (1) CA2555694C (https=)
DE (1) DE602005015544D1 (https=)
DK (1) DK1713830T3 (https=)
EA (1) EA011951B1 (https=)
ES (1) ES2328159T3 (https=)
IL (1) IL177069A (https=)
MX (1) MXPA06008942A (https=)
NO (1) NO339364B1 (https=)
NZ (1) NZ549125A (https=)
PL (1) PL1713830T3 (https=)
PT (1) PT1713830E (https=)
SI (1) SI1713830T1 (https=)
UA (1) UA87128C2 (https=)
WO (1) WO2005080428A2 (https=)
ZA (1) ZA200606083B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
CA2638040A1 (en) * 2006-02-09 2007-08-16 Micromet Ag Treatment of metastatic breast cancer
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
EP2142570B1 (en) * 2007-04-04 2011-06-15 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Anti-epcam antibody and uses thereof
US9689028B2 (en) 2008-12-22 2017-06-27 University Of Utah Foundation Monochrome multiplex quantitative PCR
AU2010295172B2 (en) * 2009-09-21 2016-08-04 Ranju Ralhan Methods and compositions for the diagnosis and treatment of thyroid cancer
TWI485161B (zh) * 2012-03-02 2015-05-21 中央研究院 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法
CN103387989B (zh) * 2012-09-24 2016-05-18 厦门大学 上皮细胞粘附分子的核酸适体EpCAM D及其制备方法
EP2999800B1 (en) 2013-05-22 2019-09-25 Telomere Diagnostics Inc. Measures of short telomere abundance
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
ES3012974T3 (en) * 2014-01-08 2025-04-10 Univ Leland Stanford Junior Targeted therapy for lung cancer
US9944978B2 (en) 2014-12-30 2018-04-17 Telomere Diagnostics, Inc. Multiplex quantitative PCR
ES2873846T5 (en) * 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
WO2003099205A2 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEWIS L.D., "Technology evaluation: ING-1, XOMA", Current Opinion in Molecular Therapeutics, vol. 5, no. 4, 2003, side 433-436, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
CN1976951A (zh) 2007-06-06
WO2005080428A3 (en) 2005-11-10
JP5220315B2 (ja) 2013-06-26
ES2328159T3 (es) 2009-11-10
EA011951B1 (ru) 2009-06-30
EP2107071A3 (en) 2009-12-30
KR20070009988A (ko) 2007-01-19
EP1713830B1 (en) 2009-07-22
EA200601386A1 (ru) 2007-06-29
ATE437186T1 (de) 2009-08-15
HK1096103A1 (en) 2007-05-25
UA87128C2 (ru) 2009-06-25
SI1713830T1 (sl) 2009-10-31
EP1713830A2 (en) 2006-10-25
KR101236224B1 (ko) 2013-02-22
BRPI0507660A (pt) 2007-07-17
CA2555694A1 (en) 2005-09-01
AU2005215874B2 (en) 2011-01-27
WO2005080428A2 (en) 2005-09-01
CA2555694C (en) 2013-04-16
NO20064136L (no) 2006-11-07
DK1713830T3 (da) 2009-10-12
AU2005215874A1 (en) 2005-09-01
PT1713830E (pt) 2009-10-19
US20120294873A1 (en) 2012-11-22
ZA200606083B (en) 2007-10-31
PL1713830T3 (pl) 2010-01-29
JP2008500277A (ja) 2008-01-10
IL177069A0 (en) 2006-12-10
CN1976951B (zh) 2012-03-14
EP2107071A2 (en) 2009-10-07
US20070274982A1 (en) 2007-11-29
NZ549125A (en) 2008-09-26
IL177069A (en) 2010-11-30
MXPA06008942A (es) 2007-01-26
US20050180979A1 (en) 2005-08-18
DE602005015544D1 (de) 2009-09-03

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
US20210324103A1 (en) Use of semaphorin-4d inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
US7794713B2 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
US20220265844A1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
EP3645040A1 (en) Use of anti-fam19a5 antibodies for treating cancers
US10507242B2 (en) Combination therapy for treating breast cancer
CN112584872A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的用途
CN121311246A (zh) 癌症治疗与预防的组合疗法
JP2019014724A (ja) 併用療法
CA2581061A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
HK1096103B (en) Anti-epcam immunoglobulins
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
CN115607663A (zh) 抗pd-1抗体在治疗原发纵隔大b细胞淋巴瘤中的应用
HK40130006A (zh) 通过施用抗her2抗体-药物缀合物治疗her2突变的癌
CN115607662A (zh) 抗pd-1抗体在治疗腺泡状软组织肉瘤中的应用
HK40051932A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AMGEN RESEARCH (MUNICH) GMBH, DE

MM1K Lapsed by not paying the annual fees